Skip to main content

/ health information/ Group items tagged esmo_2019_dates

Group items tagged

Filter: All | Bookmarks | Topics Simple Middle

ESMO 2019: Samsung Bioepis reveals Bevacizumab biosimilar trial result - 1 views

www.clinicaltrialsarena.com/...samsung-bevacizumab-biosimilar

#esmo_2019 #Samsung_Bioepis_reveals # esmo_2019_dates #Bevacizumab #biosimilar_trial_result #non_small_cell_lung_cancer.

shared by jacob logan on 03 Oct 19 - No Cached

jacob logan on 03 Oct 19

A Phase 3 study comparing Samsung Bioepis' SB8 with Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR).

<div class="cArrow"> </div><div class="cContentInner">A Phase 3 study comparing Samsung Bioepis' SB8 with Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR).</div>

...

Cancel

ESMO 2019: Seven promising liquid biopsy companies at ESMO Congress - 1 views

www.medicaldevice-network.com/...o-2019-liquid-biopsy-companies

#Liquid_Biopsy #ESMO_2019 #ESMO_Congress #Medical_Device #esmo_congress_2019 #esmo_conference_2019 #esmo_2019_dates #esmo_2019_meeting

shared by jacob logan on 27 Sep 19 - No Cached

Alex Parker on 27 Sep 19

Research and development (R&D) in liquid biopsy is increasingly being funded by both public and private sectors due to its promising features such as early detection of cancer tumour, new lesion characterisation and identification of cancer drug target.

<div class="cArrow"> </div><div class="cContentInner">Research and development (R&D) in liquid biopsy is increasingly being funded by both public and private sectors due to its promising features such as early detection of cancer tumour, new lesion characterisation and identification of cancer drug target.</div>

...

Cancel
jacob logan on 27 Sep 19

Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.

<div class="cArrow"> </div><div class="cContentInner">Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.</div>

...

Cancel

ESMO 2019: Kisqali shows superior overall survival in breast cancer - 1 views

www.clinicaltrialsarena.com/...esmo-novartis-kisqali

#ESMO_2019 #esmo_conference_2019 #esmo_congress_2019 #Breast_Cancer #esmo_2019_dates

shared by jacob logan on 07 Oct 19 - No Cached

jacob logan on 07 Oct 19

Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.

<div class="cArrow"> </div><div class="cContentInner">Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.</div>

...

Cancel

1 - 3 of 3

Showing 20▼ items per page

Related searches